Is Anti‑Cyclic Citrullinated Peptide Antibody a Good Value Biomarker for Alzheimer Disease?

Rokhsareh Meamar, Gholamreza Askari, Majid Ghasemi, Mohammad Reza Aghaye Ghazvini, Sahar Vesal, Mostafa Sharifkhah, Nazanin Alaei Faradonbeh, Leila Dehghani


Background: Alzheimer’s disease (AD) is one of the most important neurodegenerative disorder. Anti‑cyclic citrullinated peptide (anti‑CCP) may all be involved in the development of vascular disease such as AD. The aim of this study is detection of seropositivity for anti‑CCP antibody in AD patients.

Methods: In our study, 30 patients with AD and 29 healthy controls (age and‑sex matched) were recruited. Homocysteine and anti‑CCP was measured by spectrophotometrically and immunoassay.

Results: Mean ± SE anti‑CCP was higher significantly between AD (13.6 ± 3) and healthy subjects (4.8 ± 0.2) (P = 0.006). In the patients, anti‑CCP serum level was in high range (32.1%) of abnormal levels, but there was no significant difference in serum homocysteine in AD patients compared with controls. There is no correlation between anti‑CCP and homocysteine levels in AD patients (P = 0.75), but between age and anti‑CCP level observed a significantly correlation (P = 0.04).

Conclusions: It needs more studies to clarify confirmation the role of anti‑CCP antibody production in AD patients.

Keywords: Alzheimer`s disease, anti‑cyclic citrullinated peptide, homocysteine

Full Text: